Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
34 pending office actions • 10 art units • 28 examiners • 0 of 34 (0%) have an AI response strategy ready • 38 patents granted in the last 365 days
Gilead Sciences Inc. currently manages 35 pending office actions within the Biotechnology & Pharmaceuticals technology area. These matters are distributed across 29 distinct examiners and 11 distinct art units. This distribution indicates a significant spread of examination across the USPTO, with some concentration among certain examiners.
LEE, ANDREW P is identified as the busiest examiner for this portfolio, currently handling 3 pending office actions. This represents a small portion of the total 35 pending office actions. The presence of 11 distinct art units suggests that the company's biotechnology and pharmaceutical innovations span multiple specialized classifications within the patent office.
Practitioners should note that with 29 distinct examiners for 35 actions, most pending matters are being reviewed by different individuals. This limited examiner overlap means that prosecution strategies may need to be tailored to the specific preferences of many different officials. Managing 11 distinct art units requires a sophisticated understanding of various examination guidelines within the Biotechnology & Pharmaceuticals sector.
Based on the USPTO statutory response window for each pending office action. 7 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 7 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 6 (18%) |
| §102 only | 3 (9%) |
| §112 only | 9 (26%) |
| Double-patenting only | 2 (6%) |
| Double-patenting + other | 6 (18%) |
| Multi-statute (no §101) | 8 (24%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LEE, ANDREW P | 3 | 48.3% | +23.1% |
| KIFLE, BRUCK | 2 | 79.2% | +15.9% |
| SEUDIEU SEUDIEU, CARINE PATRICIA | 2 | — | — |
| MARTIN, KEVIN STEPHEN | 2 | 77.2% | +23.2% |
| FETTEROLF, BRANDON J | 2 | 52.0% | +17.4% |
| PUTTLITZ, KARL J | 1 | 69.1% | +18.6% |
| AULAKH, CHARANJIT | 1 | 80.6% | -14.5% |
| SHIAO, REI TSANG | 1 | 79.8% | -33.6% |
| HASTINGS, ALISON AZAR | 1 | 63.5% | +40.2% |
| KASSA, TIGABU | 1 | 36.7% | +27.9% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18829547 | METHODS AND INTERMEDIATES FOR PREPARING THERAPEUTIC COMPOUNDS | AULAKH, CHARANJIT | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18295163 | COMBINATION THERAPY FOR TREATING COLORECTAL CANCER | HAMA, JOANNE | 2d overdue |
| 18448721 | DOSING AND SCHEDULING REGIMEN FOR BROADLY NEUTRALIZING ANTIBODIES | GRIZER, CASSANDRA SENN | 8d |
| 18785641 | WEEKLY REGIMEN FOR HIV | SAMSELL, RILLA MARIE | — |
| 18754347 | METHODS AND INTERMEDIATES FOR PREPARING ANTIVIRAL PRODRUGS | FADHEL, ALI Z | — |
| 18678355 | SOLID FORMS | CORNET, JEAN P | — |
| 18645671 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | KRISHNAN, GANAPATHY | — |
| 18115895 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | NOTTINGHAM, KYLE GREGORY | — |
| 16882804 | THERAPEUTIC COMPOUNDS | COUGHLIN, MATTHEW P | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18313266 | DARUNAVIR COMBINATION FORMULATIONS | LEE, ANDREW P | 26d overdue |
| 19255499 | TREATMENT OF HR+/HER2- BREAST CANCER USING SACITUZUMAB GOVITECAN | PUTTLITZ, KARL J | — |
| 18938633 | MCL1 INHIBITORS | KIFLE, BRUCK | — |
| 18918629 | MCL-1 INHIBITORS | KIFLE, BRUCK | — |
| 18899540 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | MARTIN, KEVIN STEPHEN | — |
| 18818487 | SOLID FORMS OF FXR AGONISTS | MARTIN, KEVIN STEPHEN | — |
| 18812842 | DOSING REGIMEN OF HIV CAPSID INHIBITOR | HASTINGS, ALISON AZAR | — |
| 18804677 | PHARMACEUTICAL FORMULATIONS OF BICTEGRAVIR AND LENACAPAVIR | KASSA, TIGABU | — |
| Art Unit | Apps |
|---|---|
| 1626 | 3 |
| 1691 | 2 |
| 1672 | 2 |
| 1646 | 1 |
| 1693 | 1 |
| 1675 | 1 |
| 1629 | 1 |
| 1625 | 1 |
| 1647 | 1 |
| 1621 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19255499 | TREATMENT OF HR+/HER2- BREAST CANCER USING SACITUZUMAB GOVITECAN | PUTTLITZ, KARL J | 1646 | §103§112DP | Final Rejection | — | Pending | Jun 30, 2025 |
| 18938633 | MCL1 INHIBITORS | KIFLE, BRUCK | — | §112Other | Non-Final OA | — | Pending | Nov 06, 2024 |
| 18918629 | MCL-1 INHIBITORS | KIFLE, BRUCK | — | §112Other | Non-Final OA | — | Pending | Oct 17, 2024 |
| 18911340 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF | SEUDIEU SEUDIEU, CARINE PATRICIA | — | §102Other | Non-Final OA | — | Pending | Oct 10, 2024 |
| 18911404 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF | SEUDIEU SEUDIEU, CARINE PATRICIA | — | §102Other | Non-Final OA | — | Pending | Oct 10, 2024 |
| 18899540 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | MARTIN, KEVIN STEPHEN | — | §112 | Non-Final OA | — | Pending | Sep 27, 2024 |
| 18829547 | METHODS AND INTERMEDIATES FOR PREPARING THERAPEUTIC COMPOUNDS | AULAKH, CHARANJIT | — | §112DP | Non-Final OA | — | Pending | Sep 10, 2024 |
| 18827510 | KRAS G12D MODULATING COMPOUNDS | SHIAO, REI TSANG | — | §102§103DP | Non-Final OA | — | Pending | Sep 06, 2024 |
| 18818487 | SOLID FORMS OF FXR AGONISTS | MARTIN, KEVIN STEPHEN | — | §112Other | Non-Final OA | — | Pending | Aug 28, 2024 |
| 18812842 | DOSING REGIMEN OF HIV CAPSID INHIBITOR | HASTINGS, ALISON AZAR | — | §102§103DP | Non-Final OA | — | Pending | Aug 22, 2024 |
| 18804677 | PHARMACEUTICAL FORMULATIONS OF BICTEGRAVIR AND LENACAPAVIR | KASSA, TIGABU | — | §103 | Non-Final OA | — | Pending | Aug 14, 2024 |
| 18785641 | WEEKLY REGIMEN FOR HIV | SAMSELL, RILLA MARIE | — | §102§103§112Other | Non-Final OA | — | Pending | Jul 26, 2024 |
| 18759283 | SALTS AND SOLID FORMS OF A COMPOUND THAT MODULATES IRAK4 | KOSAR, ANDREW D | — | §112 | Non-Final OA | — | Pending | Jun 28, 2024 |
| 18758879 | PROCESSES FOR MAKING IRAK4 INHIBITORS | FETTEROLF, BRANDON J | — | §102 | Final Rejection | — | Pending | Jun 28, 2024 |
| 18754347 | METHODS AND INTERMEDIATES FOR PREPARING ANTIVIRAL PRODRUGS | FADHEL, ALI Z | — | §102§103 | Non-Final OA | — | Pending | Jun 26, 2024 |
| 18747316 | FXR (NR1H4) MODULATING COMPOUNDS | HOWELL, THEODORE R | — | DP | Non-Final OA | — | Pending | Jun 18, 2024 |
| 18731608 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF | LEE, ANDREW P | — | DP | Non-Final OA | — | Pending | Jun 03, 2024 |
| 18678355 | SOLID FORMS | CORNET, JEAN P | — | §103§112Other | Non-Final OA | — | Pending | May 30, 2024 |
| 18678444 | THERAPEUTIC COMPOUNDS FOR HIV | WHITE, DAWANNA SHAR-DAY | — | §103 | Non-Final OA | — | Pending | May 30, 2024 |
| 18673168 | ANTIVIRAL COMPOUNDS | LEE, ANDREW P | 1691 | §112 | Final Rejection | — | Pending | May 23, 2024 |
| 18655876 | METHODS OF PREPARING 1'-CYANO NUCLEOSIDES | BERRY, LAYLA D | 1693 | §103 | Final Rejection | 5d overdue | Pending | May 06, 2024 |
| 18645671 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | KRISHNAN, GANAPATHY | — | §103§112 | Non-Final OA | — | Pending | Apr 25, 2024 |
| 18540652 | INTERLEUKIN-2-Fc FUSION PROTEINS AND METHODS OF USE | STOICA, ELLY GERALD | — | §112 | Non-Final OA | — | Pending | Dec 14, 2023 |
| 18499540 | ANTICANCER THERAPIES USING ANTI-CCR8 ANTIBODY, CHEMO AND IMMUNOTHERAPY COMBINATIONS | BERHANE, SELAM | 1675 | §112 | Non-Final OA | — | Pending | Nov 01, 2023 |
| 18448721 | DOSING AND SCHEDULING REGIMEN FOR BROADLY NEUTRALIZING ANTIBODIES | GRIZER, CASSANDRA SENN | 1672 | §103§112 | Final Rejection | 8d | Pending | Aug 11, 2023 |
| 18346745 | BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF | FETTEROLF, BRANDON J | 1626 | §112DPOther | Final Rejection | — | Pending | Jul 03, 2023 |
| 18344560 | CD73 COMPOUNDS | SEITZ, ANTHONY JOSEPH | 1629 | §112 | Non-Final OA | 69d | Pending | Jun 29, 2023 |
| 18205745 | METHODS FOR TREATMENT OF VIRAL INFECTIONS | MAHLUM, JONATHAN DAVIS | 1625 | §103§112DP | Non-Final OA | — | Pending | Jun 05, 2023 |
| 18313266 | DARUNAVIR COMBINATION FORMULATIONS | LEE, ANDREW P | 1691 | §103 | Non-Final OA | 26d overdue | Pending | May 05, 2023 |
| 18295163 | COMBINATION THERAPY FOR TREATING COLORECTAL CANCER | HAMA, JOANNE | 1647 | §103§112Other | Non-Final OA | 2d overdue | Pending | Apr 03, 2023 |
| 18115895 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | NOTTINGHAM, KYLE GREGORY | 1621 | §102§103§112 | Non-Final OA | — | Pending | Mar 01, 2023 |
| 17636511 | PHARMACEUTICAL FORMULATIONS OF TENOFOVIR ALAFENAMIDE | JACKSON, SHAWQUIA | 1626 | §103 | Non-Final OA | 77d | Pending | Feb 18, 2022 |
| 17612426 | DOSAGE REGIMENS FOR VACCINES | JADHAO, SAMADHAN JAISING | 1672 | §103Other | Final Rejection | 31d overdue | Pending | Nov 18, 2021 |
| 16882804 | THERAPEUTIC COMPOUNDS | COUGHLIN, MATTHEW P | 1626 | §102§112 | Non-Final OA | — | Pending | May 26, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial